Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Accumulated Depreciation & Amortization (2016 - 2025)

ImmunityBio (IBRX) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 11.56% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, down 11.56% year-over-year, with the annual reading at $15.5 million for FY2025, 11.56% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $15.5 million at ImmunityBio, up from $11.7 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $18.5 million in Q4 2023, with the low at $3.0 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $10.4 million, with a median of $10.0 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization tumbled 85.73% in 2021, then surged 37.62% in 2022.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $14.2 million in 2021, then increased by 28.25% to $18.3 million in 2022, then rose by 1.38% to $18.5 million in 2023, then fell by 5.18% to $17.6 million in 2024, then dropped by 11.56% to $15.5 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $15.5 million, $11.7 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.